Inactive/Delisted stock
Biomea Fusion Stock (NASDAQ:BMEA)
Previous Close
$1.46
52W Range
$1.38 - $13.43
50D Avg
$2.16
200D Avg
$5.46
Market Cap
$53.73M
Avg Vol (3M)
$706.64K
Beta
-0.08
Div Yield
-
BMEA Company Profile
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.